{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:20:29Z","timestamp":1789842029536,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12288-021-01450-9","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T19:02:51Z","timestamp":1622142171000},"page":"290-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma\u2014A Single Center Experience"],"prefix":"10.1007","volume":"38","author":[{"given":"Jayastu","family":"Senapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup J.","family":"Devasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Korula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. A.","family":"Fouzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha M.","family":"Lakshmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Lionel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-9501","authenticated-orcid":false,"given":"Biju","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"1450_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomized trials. Lancet 341:1051\u20131054","journal-title":"Lancet"},{"key":"1450_CR2","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomized trial. Lancet 359:2065\u20132071","journal-title":"Lancet"},{"key":"1450_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjh.15639","volume":"184","author":"A Broccoli","year":"2019","unstructured":"Broccoli A, Zinzani PL (2019) The role of transplantation in Hodgkins lymphoma. Br J Haematol 184:93\u2013104","journal-title":"Br J Haematol"},{"key":"1450_CR4","first-page":"221","volume":"20","author":"A Josting","year":"2002","unstructured":"Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J et al (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group. J Clin Oncol 20:221\u2013230","journal-title":"J Clin Oncol"},{"key":"1450_CR5","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.3109\/10428194.2013.854888","volume":"55","author":"B von Tresckow","year":"2014","unstructured":"von Tresckow B, Muller H, Eichenauer DA, Glossmann JP, Josting A, Boll B et al (2014) Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 55:1922\u20131924","journal-title":"Leuk Lymphoma"},{"key":"1450_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ et al (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol 16:625\u2013633","journal-title":"Ann Oncol"},{"issue":"15","key":"1450_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","volume":"131","author":"G Shah","year":"2018","unstructured":"Shah G, Moskowitz C (2018) Transplant strategies in relapsed\/refractory Hodgkins lymphoma. Blood 131(15):1689\u20131697","journal-title":"Blood"},{"issue":"19","key":"1450_CR8","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812\u20132182","journal-title":"N Engl J Med"},{"key":"1450_CR9","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35:2125\u20132132","journal-title":"J Clin Oncol"},{"key":"1450_CR10","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36:1428\u20131439","journal-title":"J Clin Oncol"},{"issue":"12","key":"1450_CR11","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT et al (2015) Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 21(12):2136\u20132140","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1450_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Sch\u00f6der H, Yahalom J, McCall SJ, Fox SY, Gerecitano J et al (2015) PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 16(3):284\u2013292","journal-title":"Lancet Oncol"},{"key":"1450_CR13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853\u20131862","journal-title":"Lancet"},{"issue":"8","key":"1450_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","volume":"98","author":"E Van Den Neste","year":"2013","unstructured":"Van Den Neste E, Casasnovas O, Andre M, Touati M, Senecal D, Edeline V et al (2013) Classical Hodgkin\u2019s lymphoma: the Lymphoma Study association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica 98(8):1185\u20131195","journal-title":"Haematologica"},{"issue":"27","key":"1450_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for Initial evaluation, staging and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133067","journal-title":"J Clin Oncol"},{"key":"1450_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M et al (2015) Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:1046\u20131053","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"1450_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00277-011-1205-4","volume":"90","author":"L Kumar","year":"2011","unstructured":"Kumar L, Malik PS, Prakash G, Prabu R, Radhakrishnan V, Katyal S et al (2011) Autologous hematopoietic stem cell transplantation\u2014what determines the outcome: an experience from North India. Ann Hematol 90(11):1317\u20131328","journal-title":"Ann Hematol"},{"issue":"5","key":"1450_CR18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.4103\/0973-1482.181183","volume":"14","author":"A Gupta","year":"2018","unstructured":"Gupta A, Gokarn A, Rajamanickam D, Punatar S, Thippeswamy R, Mathew L et al (2018) Lomustine, Cytarabine, Cyclophosphamide, Etoposide\u2014an effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: analysis of toxicity, long term outcome and prognostic factors. J Cancer Res Ther Jul-Sep 14(5):926\u2013933","journal-title":"J Cancer Res Ther Jul-Sep"},{"key":"1450_CR19","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A et al; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Identification of prognostic factors predicting outcome in Hodgkin\u2019s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013; 24(9): 2430\u20132434","DOI":"10.1093\/annonc\/mdt206"},{"issue":"3","key":"1450_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hon.2604","volume":"37","author":"G Fatobene","year":"2019","unstructured":"Fatobene G, Linardi CG, Moreira F, Targueta GMF, Maria Santos F, Velasques RD et al (2019) Reassessment of risk factors and long-term results of autologous stem cell transplantation in relapsed and refractory classical hodgkin lymphoma. Haematol Oncol 37(3):310\u2013313","journal-title":"Haematol Oncol"},{"issue":"23","key":"1450_CR21","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116(23):4934\u20134937","journal-title":"Blood"},{"issue":"5","key":"1450_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","volume":"95","author":"HJA Adams","year":"2016","unstructured":"Adams HJA, Kwee TC (2016) Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol 95(5):695\u2013706","journal-title":"Ann Hematol"},{"issue":"10","key":"1450_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"12","author":"NS Majhail","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A et al (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant 12(10):1065\u20131072","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1450_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/sj.bmt.1704789","volume":"35","author":"T Hahn","year":"2005","unstructured":"Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM et al (2005) A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin\u2019s disease. Bone Marrow Transplant 35(6):557\u2013566","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 2","key":"1450_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/hon.2437_73","volume":"35","author":"AF Herrera","year":"2017","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramachandren R, Feldman TA et al (2017) Interim results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Hematol Oncol 35(suppl 2):85\u201386","journal-title":"Hematol Oncol"},{"issue":"3","key":"1450_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12185-015-1927-5","volume":"103","author":"N Khattry","year":"2016","unstructured":"Khattry N, Gupta A, Jain R, Gore A, Thippeswamy R, Jeevangi N et al (2016) LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy. Int J Hematol 103(3):292\u2013298","journal-title":"Int J Hematol"},{"issue":"7","key":"1450_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/bmt.2014.39","volume":"49","author":"M Mohty","year":"2014","unstructured":"Mohty M, Hubel K, Kroger N, Aljurf M, Apperley J, Basak GW et al (2014) Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 49(7):865\u2013872","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1450_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/cid\/ciy955","volume":"69","author":"S Gandra","year":"2019","unstructured":"Gandra S, Tseng KK, Arora A, Bhowmik B, Robinson ML, Panigrahi B et al (2019) The mortality burden of multi-drug resistant pathogens in India: a retrospective, observational study. Clin Infect Dis 69(4):563\u2013570","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1450_CR29","first-page":"1","volume":"8","author":"M Carlsten","year":"2019","unstructured":"Carlsten M, Jadersten M, Hellstrom A, Melen CM, Junlen HR, Sonnevi K et al (2019) The Karolinska experience of autologous stem cell transplantation for lymphoma: a population based study of all 433 patients. 1994\u20132016. Exp Hematol Oncol 8(7):1\u201312","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"1450_CR30","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/j.bbmt.2020.08.017","volume":"26","author":"L Shea","year":"2020","unstructured":"Shea L, Watkins MP, Wan F, Cashen A, Wagner-Johnston N, Jacoby M et al (2020) A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory Hodgkins lymphoma. Biol Blood Marrow Transplant 26(12):2223\u20132228","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01450-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-021-01450-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01450-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T02:06:33Z","timestamp":1649729193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-021-01450-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1007\/s12288-021-01450-9","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interest for any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Retrospective study \u2013 IRB approval obtained for this retrospective analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Additional declarations for articles in life science journals that report the results of studies involving humans and\/or animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Obtained from authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}